Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...

Ojjaara is the only once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor.x The approval of Ojjaara by Health Canada is supported by data from the pivotal MOMENTUM Phase III trial ...

Merck & Co. said Friday that Canada's Drug Agency recommended the company's Winrevair for reimbursement as a treatment for adults with pulmonary arterial hypertension. The agency recommended the ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that Canada's Drug Agency (CDA) has ...

Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial ...

WVE-007 (INHBE GalNAc-siRNA for obesity) is on track to initiate a clinical trial in 1Q 2025; new preclinical data for ...

Analysis in melanoma cells reveals that proteolytic maturation of Activin-A is regulated by the connectivity of disulfide bonds near the furin cleavage site and stimulates tumor growth only if ...

Aging is an intricate biological process involving gradual changes at the cellular, molecular, and genetic levels (Lopez-Otin et al., 2023; Herndon et al., 2002). These changes lead to the decline of ...

We verified the secreted senescence markers, PAI-1 (plasminogen activator inhibitor 1) and activin A, as identified in our single-nucleus RNA sequencing model as predictive markers before clinical ...

"NI 43-101 Technical Report and Mineral Resource Estimate for the Croinor Gold Property, Quebec”, prepared by InnovExplo Inc., dated October 18, 2024, with an effective date of June 17, 2024.

免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场 ...